TNBC
-
Datopotamab Deruxtecan Shows Unprecedented Survival Benefit in Metastatic Triple-Negative Breast Cancer
AstraZeneca and Daiichi Sankyo’s DATROWAY met dual primary endpoints in the TROPION-Breast02 Phase III trial for locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) patients. DATROWAY demonstrated a statistically significant and clinically meaningful improvement in both overall survival (OS) and progression-free survival (PFS) versus chemotherapy. The trial showed a 43% reduction in disease progression or death risk and a 5-month improvement in median OS versus chemotherapy. Detailed results will be presented at the 2025 ESMO Congress.
